Prescription medicine
Fluorodopa f 18
Fluorodopa f 18 is a prescription medicine with an FDA approval on record since 2019. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the fluorodopa f 18 FDA label on DailyMed (effective January 15, 2021, THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH); the NDA 200655 record on Drugs@FDA; every fluorodopa f 18 label on DailyMed.
Highlights of the record
FDA label of January 15, 2021; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageFluorodopa F 18 Injection is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS).
Forms and strengths
Injection.
On the market
- Earliest approval on file
- October 10, 2019 Fluorodopa F18, Feinstein; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is fluorodopa f 18 used for?
From the label: indications and usageFluorodopa F 18 Injection is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations. Fluorodopa F 18 Injection is a radioactive diagnostic agent indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.
Source: FDA drug label (Fluorodopa F18), THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH, effective January 15, 2021 (SPL set 37f8c405-ccb6-4fcd-8513-108956bb1674), via openFDA; the full label on DailyMed
Is there a generic for fluorodopa f 18?
No generic fluorodopa f 18 is approved (Drugs@FDA, October 8, 2026).
- 2019 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the fluorodopa f 18 label say about other medicines?
The fluorodopa f 18 label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Amphetamine | drug interactions | … dopamine agonists, dopamine reuptake inhibitors, dopamine releasing agents (DRAs) such as psychostimulants of the amphetamine class, peripheral catechol-O-methyltransferase (COMT) inhibitors, and monoamine oxidase (MAO) inhibitors. |
| Carbidopa | drug interactions | DRUG INTERACTIONS Aromatic L-amino acid decarboxylase (AADC) inhibitors Prior to Fluorodopa F 18 Injection administration, use of AADC inhibitors (e.g. carbidopa, benserazide etc.) may increase Fluorodopa F 18 bioavailability to the brain by inhibiting peripheral decarboxylase activity and restricting peripheral … |
Source: FDA drug label (Fluorodopa F18), THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH, effective January 15, 2021 (SPL set 37f8c405-ccb6-4fcd-8513-108956bb1674), via openFDA; the full label on DailyMed
What next?
- Check an interaction
- what two or more labels say about each other